Drug Profile
Research programme: stroke therapies - PYC Therapeutics
Alternative Names: PYC-35T; PYC-36SLatest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Phylogica
- Developer PYC Therapeutics
- Class Peptide fragments
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 18 Aug 2005 The programme is available for licensing (http://www.phylogica.com)
- 19 Jul 2004 Early research in Stroke in Australia (IV-injection)